Targeted therapy for metastatic renal cell carcinoma

Review (8 RCTs; n=11,590) concluded several combinations of immune checkpoint inhibitors appear to be superior to single‐agent targeted therapy in terms of progression and overall survival, and with a favourable adverse effect profile.

Cochrane Database of Systematic Reviews